Willem J. Remme

29.4k total citations · 6 hit papers
154 papers, 20.9k citations indexed

About

Willem J. Remme is a scholar working on Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Willem J. Remme has authored 154 papers receiving a total of 20.9k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Cardiology and Cardiovascular Medicine, 25 papers in Radiology, Nuclear Medicine and Imaging and 16 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Willem J. Remme's work include Heart Failure Treatment and Management (79 papers), Cardiac electrophysiology and arrhythmias (45 papers) and Blood Pressure and Hypertension Studies (44 papers). Willem J. Remme is often cited by papers focused on Heart Failure Treatment and Management (79 papers), Cardiac electrophysiology and arrhythmias (45 papers) and Blood Pressure and Hypertension Studies (44 papers). Willem J. Remme collaborates with scholars based in Netherlands, United Kingdom and France. Willem J. Remme's co-authors include Faı̈ez Zannad, Bertram Pitt, A.J. Pérez Pérez, A Castaigne, Robert Cody, Janet Wittes, Karl Swedberg, Richard M. Bittman, James D. Neaton and Barbara Roniker and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Willem J. Remme

149 papers receiving 19.8k citations

Hit Papers

The Effect of Spironolactone on Morbidity and Mortality i... 1986 2026 1999 2012 1999 2003 2000 2005 2003 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
    1999 6.4k citations Faı̈ez Zannad, Willem J. Remme et al. profile →
  2. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
    2003 3.4k citations Willem J. Remme, Faı̈ez Zannad et al. profile →
  3. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
    2000 2.4k citations Faı̈ez Zannad, Willem J. Remme et al. profile →
  4. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
    2005 1.7k citations Karl Swedberg, John G.F. Cleland et al. European Heart Journal profile →
  5. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    2003 1.3k citations Philip A. Poole‐Wilson, Karl Swedberg et al. profile →
  6. Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival
    1986 405 citations Maarten L. Simoons, Willem J. Remme et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Willem J. Remme Netherlands 41 16.1k 6.6k 3.7k 3.3k 2.2k 154 20.9k
Robert Cody United States 43 13.0k 0.8× 4.3k 0.6× 2.9k 0.8× 3.3k 1.0× 1.9k 0.9× 153 17.4k
A Castaigne France 28 11.0k 0.7× 4.7k 0.7× 2.6k 0.7× 2.3k 0.7× 1.4k 0.6× 108 14.2k
Jan Östergren Sweden 48 14.2k 0.9× 5.6k 0.8× 4.7k 1.3× 2.0k 0.6× 897 0.4× 140 19.7k
Michel Komajda France 77 22.2k 1.4× 4.2k 0.6× 2.5k 0.7× 2.6k 0.8× 3.9k 1.7× 355 26.8k
Roland E. Schmieder Germany 74 20.0k 1.2× 7.8k 1.2× 4.0k 1.1× 2.9k 0.9× 2.3k 1.0× 623 29.3k
Giuseppe Rosano Italy 59 11.1k 0.7× 4.3k 0.6× 2.7k 0.7× 1.7k 0.5× 2.1k 0.9× 307 18.2k
Eric L. Michelson United States 58 17.7k 1.1× 3.2k 0.5× 2.0k 0.5× 2.3k 0.7× 1.2k 0.5× 192 20.9k
Akshay S. Desai United States 71 16.9k 1.0× 4.7k 0.7× 2.3k 0.6× 3.8k 1.2× 1.6k 0.7× 386 21.2k
John Kjekshus Norway 68 15.7k 1.0× 6.1k 0.9× 11.0k 2.9× 2.4k 0.7× 2.6k 1.2× 238 28.2k
Luís M. Ruilope Spain 76 20.0k 1.2× 10.2k 1.5× 4.8k 1.3× 3.5k 1.1× 2.9k 1.3× 763 31.0k

Countries citing papers authored by Willem J. Remme

Since Specialization
Citations

This map shows the geographic impact of Willem J. Remme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willem J. Remme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willem J. Remme more than expected).

Fields of papers citing papers by Willem J. Remme

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willem J. Remme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willem J. Remme. The network helps show where Willem J. Remme may publish in the future.

Co-authorship network of co-authors of Willem J. Remme

This figure shows the co-authorship network connecting the top 25 collaborators of Willem J. Remme. A scholar is included among the top collaborators of Willem J. Remme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willem J. Remme. Willem J. Remme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leeuw, Joep van der, Rohit M. Oemrawsingh, Yolanda van der Graaf, et al.. (2014). Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease — Results from EUROPA. International Journal of Cardiology. 182. 194–199. 8 indexed citations
2.
Castagno, Davide, Erland Erdmann, Faı̈ez Zannad, et al.. (2011). Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II). Cardiovascular Drugs and Therapy. 25(1). 77–85. 10 indexed citations
3.
Castagno, Davide, Pardeep S. Jhund, John J.V. McMurray, et al.. (2010). Improved Survival with Bisoprolol in Patients with Heart Failure and Renal Impairment: An Analysis of the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) Trial. European Journal of Heart Failure. 12(6). 607–616. 62 indexed citations
4.
Levy, Wayne C., Dariush Mozaffarian, David T. Linker, et al.. (2009). Years-Needed-To-Treat to Add 1 Year of Life: A New Metric to Estimate Treatment Effects in Randomized Trials. European Journal of Heart Failure. 11(3). 256–263. 9 indexed citations
5.
Brugts, Jasper J., Moniek P.M. de Maat, Eric Boersma, et al.. (2008). Abstract 2456: Strong and Independent Association between Angiotensinogen Gene Polymorphisms and Hypertension in 10060 Patients with Stable Coronary Artery Disease. Circulation. 118. 1 indexed citations
6.
Remme, Willem J., John G.F. Cleland, Leif Erhardt, et al.. (2007). Effect of Carvedilol and Metoprolol on the Mode of Death in Patients with Heart Failure. European Journal of Heart Failure. 9(11). 1128–1135. 29 indexed citations
7.
Olsson, Lars, Karl Swedberg, John G.F. Cleland, et al.. (2007). Prognostic Importance of Plasma NT-Pro BNP in Chronic Heart Failure in Patients Treated with a β-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) Trial. European Journal of Heart Failure. 9(8). 795–801. 60 indexed citations
8.
Metra, Marco, Christian Torp‐Pedersen, John G.F. Cleland, et al.. (2007). Should Beta-Blocker Therapy be Reduced or Withdrawn After an Episode of Decompensated Heart Failure? Results from COMET. European Journal of Heart Failure. 9(9). 901–909. 79 indexed citations
9.
Cleland, John G.F., Andrew Charlesworth, Jacobus Lubsen, et al.. (2006). A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the “Patient Journey”) in Patients With Heart Failure. Journal of the American College of Cardiology. 47(8). 1603–1611. 45 indexed citations
10.
Remme, Willem J., John J.V. McMurray, Bernhard Rauch, et al.. (2005). Public awareness of heart failure in Europe: first results from SHAPE. European Heart Journal. 26(22). 2413–2421. 91 indexed citations
11.
Lenarda, Andrea Di, Willem J. Remme, Andrew Charlesworth, et al.. (2005). Exchange of β-Blockers in Heart Failure Patients. Experiences from the Poststudy Phase of COMET (the Carvedilol or Metoprolol European Trial). European Journal of Heart Failure. 7(4). 640–649. 27 indexed citations
12.
Komajda, Michel, Beatrix Lutiger, Hugo Madeira, et al.. (2004). Tolerability of Carvedilol and ACE-Inhibition in Mild Heart Failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). European Journal of Heart Failure. 6(4). 467–475. 55 indexed citations
13.
Lenarda, Andrea Di, Philip A. Poole‐Wilson, John G.F. Cleland, et al.. (2004). 1001-26 Exchange of beta-blocking therapy in heart failure patients. Experiences from the post study phase of COMET (the carvedilol or metoprolol European trial). Journal of the American College of Cardiology. 43(5). A7–A7. 2 indexed citations
14.
Metra, Marco, Philip A. Poole‐Wilson, John G.F. Cleland, et al.. (2004). 835-3 Beta-blocker dose does not influence the beneficial effects of carvedilol compared to metroprolol in the patients with heart failure: Results from the carvedilol or Metoprolol European Trial (COMET). Journal of the American College of Cardiology. 43(5). A206–A206. 3 indexed citations
15.
Remme, Willem J., Per Hildebrandt, Michel Komajda, et al.. (2003). Do patients necessarily have to start with an angiotension converting enzyme inhibitor in the treatment of heart failure? Results of the CARMEN (Carvedilol ACE Inhibitor Remodeling Mild CHF Evaluation) study. Journal of the American College of Cardiology. 41(6). 162–162. 3 indexed citations
16.
Grobbee, Diederick E., et al.. (1999). Drug-induced heart failure. Journal of the American College of Cardiology. 33(5). 1152–1162. 67 indexed citations
17.
Simoons, Maarten L., et al.. (1998). EUROPA substudies, confirmation of pathophysiological concepts. EUR Research Repository (Erasmus University Rotterdam). 6 indexed citations
18.
Konstam, Marvin A. & Willem J. Remme. (1998). Treatment guidelines in heart failure. Progress in Cardiovascular Diseases. 41(1). 65–72. 13 indexed citations
19.
Cleland, John G.F., M. R. Bristow, Erland Erdmann, et al.. (1996). Beta-blocking agents in heart failure Should they be used and how?. European Heart Journal. 17(11). 1629–1639. 67 indexed citations
20.
Remme, Willem J., Dick A.C.M. Kruyssen, Maxime P. Look, Marianne Bootsma, & Peter W. de Leeuw. (1994). Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans. Journal of the American College of Cardiology. 23(1). 82–91. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert Cody Breakdown of academic impact, for papers by A Castaigne Breakdown of academic impact, for papers by Jan Östergren Breakdown of academic impact, for papers by Michel Komajda Breakdown of academic impact, for papers by Roland E. Schmieder Breakdown of academic impact, for papers by Giuseppe Rosano Breakdown of academic impact, for papers by Eric L. Michelson Breakdown of academic impact, for papers by Akshay S. Desai Breakdown of academic impact, for papers by John Kjekshus Breakdown of academic impact, for papers by Luís M. Ruilope
Rankless by CCL
2026